Zhejiang Xinguang Pharmaceutical Co., Ltd. (300519.SZ)
CNY 14.39
(-0.14%)
CNY 14.39
(-0.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 53.29 Million | 126.42 Million | 142.35 Million | 112.61 Million | 98.26 Million | 92.77 Million |
| Net Income | 64.35 Million | 108.82 Million | 114.28 Million | 98.97 Million | 93.9 Million | 87.99 Million |
| Depreciation & Amortization | 14.77 Million | 14.05 Million | 12.86 Million | 12.52 Million | 10.19 Million | 7.86 Million |
| Deferred income taxes | 149.52 Thousand | -110.91 Thousand | -49.91 Thousand | -117.83 Thousand | -285.81 Thousand | 78.32 Thousand |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -21.82 Million | 7.23 Million | 20.43 Million | 6.97 Million | -2.22 Million | 5.2 Million |
| Other non-cash items | -14.46 Million | -3.68 Million | -5.21 Million | -5.86 Million | -3.6 Million | -8.29 Million |
| Investing Cash Flow | -51.37 Million | -2.06 Million | -44.53 Million | 143.88 Million | -49.4 Million | -22.82 Million |
| Investments in PPE | -15.98 Million | -16.64 Million | -14.71 Million | -10.26 Million | -15.99 Million | -21.26 Million |
| Acquisitions | 320.8 Thousand | 28 Thousand | 200 Thousand | 11.79 Million | 320 Million | 129.12 Thousand |
| Investment purchases | -500 Million | -410 Million | -415 Million | -185 Million | -320 Million | -340 Million |
| Sales/Maturities of investments | 4.29 Million | 4.54 Million | 9.97 Million | 9.36 Million | 6.59 Million | 8.31 Million |
| Other Investing Activities | -40 Million | 420 Million | 375 Million | 318 Million | -39.99 Million | -9.87 Million |
| Financing Cash Flow | -80 Million | -96 Million | -96 Million | -72 Million | -48 Million | -40 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -80 Million | -96 Million | -96 Million | -72 Million | -48 Million | -40 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | 14.39 Million | -8.43 Million | 2.92 Million | -511.73 Thousand | -1.57 Million | 10.45 Million |
| Accounts payables | -10.6 Million | 15.37 Million | 22.01 Million | 1.52 Million | -5.8 Million | - |
| Inventory | -25.77 Million | 416.25 Thousand | -4.46 Million | 6.07 Million | 5.44 Million | -11.89 Million |
| Other working capital | -10.45 Million | -110.91 Thousand | -49.91 Thousand | -117.83 Thousand | -285.81 Thousand | 17.09 Million |
| Cash at beginning of period | 622.02 Million | 593.66 Million | 591.84 Million | 407.35 Million | 406.48 Million | 376.53 Million |
| Cash at end of period | 543.94 Million | 622.02 Million | 593.66 Million | 591.84 Million | 407.35 Million | 406.48 Million |
| Capital Expenditure | -15.98 Million | -16.64 Million | -14.71 Million | -10.26 Million | -15.99 Million | -21.26 Million |
| Effect of forex changes on cash | -1.00 | 0.08 | -0.05 | 1.00 | 0.55 | 0.67 |
| Net cash flow / Change in cash | -78.08 Million | 28.36 Million | 1.82 Million | 184.49 Million | 862.96 Thousand | 29.94 Million |
| Free Cash Flow | 37.3 Million | 109.78 Million | 127.64 Million | 102.34 Million | 82.27 Million | 71.5 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | 2.67 Million | 22.83 Million | 5.65 Million | 64.35 Million | 20.16 Million |
| Depreciation & Amortization | - | 3.66 Million | 3.66 Million | 14.77 Million | 14.77 Million | -7.39 Million |
| Deferred income taxes | - | - | - | - | 149.52 Thousand | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | -11.37 Million | -21.82 Million | -5.66 Million |
| Other non-cash items | - | -9.29 Million | 17.2 Million | 2.48 Million | -14.46 Million | 6.67 Million |
| Investing Cash Flow | -54.19 Million | -51 Million | 11.86 Million | -71.86 Million | -51.37 Million | 45.63 Million |
| Investments in PPE | -384.24 Thousand | -1 Million | -3.23 Million | -8.1 Million | -15.98 Million | -5.57 Million |
| Acquisitions | - | - | 100 Thousand | 300.8 Thousand | 320.8 Thousand | -315 Million |
| Investment purchases | - | -275 Million | - | -500 Million | -500 Million | 315 Million |
| Sales/Maturities of investments | 1.18 Million | 240 Million | 1.16 Million | 943.72 Thousand | 4.29 Million | 1.21 Million |
| Other Investing Activities | -55 Million | -15 Million | 15 Million | -65 Million | -40 Million | 50 Million |
| Financing Cash Flow | - | -64 Million | - | - | -80 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | -80 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -64 Million | - | - | - | - |
| Accounts receivables | - | - | - | 14.39 Million | 14.39 Million | -13.55 Million |
| Accounts payables | - | - | - | - | -10.6 Million | - |
| Inventory | - | - | - | -25.77 Million | -25.77 Million | 7.89 Million |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 470.55 Million | 595.84 Million | 543.94 Million | 604.26 Million | 622.02 Million | 546.07 Million |
| Cash at end of period | 424.61 Million | 470.55 Million | 595.84 Million | 543.94 Million | 543.94 Million | 604.26 Million |
| Capital Expenditure | -384.24 Thousand | -1 Million | -3.23 Million | -8.1 Million | -15.98 Million | -5.57 Million |
| Effect of forex changes on cash | - | - | - | - | -1.00 | - |
| Net cash flow / Change in cash | -45.94 Million | -125.29 Million | 51.89 Million | -60.31 Million | -78.08 Million | 58.19 Million |
| Free Cash Flow | -384.24 Thousand | -11.29 Million | 36.79 Million | 3.43 Million | 37.3 Million | 8.19 Million |
NEVPF
LFLO
SOBA
CZNL
FKYS
300504